Reading current FDA and NMPA trends: What oncology tells us about the changing regulatory landscape
The regulatory environment for drug development is transforming rapidly. Both the U.S. Food and Drug Administration (FDA) and China's National Medical Products Administration (NMPA) are implementing modernization agendas designed to accelerate drug development, expand regulatory flexibility, and support innovative therapies.
This comprehensive analysis examines the real-world impact of these regulatory shifts through the lens of oncology—a therapeutic area that accounts for approximately 30% of the drug development pipeline. Using data from 2024 and 2025, Parexel regulatory experts reveal key trends in IND submissions, expedited review designations, and novel drug approvals across both jurisdictions.
What you'll learn
✓ FDA and NMPA modernization initiatives reshaping development timelines
✓ Real performance data on submissions, expedited designations, and approvals
✓ How the FDA-NMPA approval gap has narrowed to just 3-5 months
✓ Strategic advantages of parallel U.S.-China development programs
✓ Organizational requirements for integrated global development
Related Insights
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
CTB Blog
Five Practical Strategies for Accelerating Early Phase Studies
Aug 19, 2026
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
Blog
A Deep Dive into the Genetic Therapies Bootcamp at the ACMG 2026 Annual Meeting
Jun 23, 2026
Video
Bench-to-bedside: Transforming scientific breakthroughs into clinical success
Apr 3, 2026
CTB Blog
Even when capital flows freely, biotechs benefit from efficiency
Mar 24, 2026
CTB Blog
5 ways to secure biotech funding in 2026
Mar 19, 2026
Article
Case study: Protecting Phase 2 obesity retention and study timelines
Mar 18, 2026
CTB Webinar
Extend your funding runway: How to maintain capital efficiency in an improving market
Mar 10, 2026
Blog
Bolster your investor narrative with RWE
Jan 26, 2026
Blog
Investor-ready evidence planning: Why a robust strategy matters to funders
Dec 8, 2025
Playbook
Strategic outsourcing redefined: Building partnerships that propel innovation
Dec 5, 2025
Related Insights
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
CTB Blog
Five Practical Strategies for Accelerating Early Phase Studies
Aug 19, 2026
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
Blog
A Deep Dive into the Genetic Therapies Bootcamp at the ACMG 2026 Annual Meeting
Jun 23, 2026
Video
Bench-to-bedside: Transforming scientific breakthroughs into clinical success
Apr 3, 2026
CTB Blog
Even when capital flows freely, biotechs benefit from efficiency
Mar 24, 2026
CTB Blog
5 ways to secure biotech funding in 2026
Mar 19, 2026
Article
Case study: Protecting Phase 2 obesity retention and study timelines
Mar 18, 2026
CTB Webinar
Extend your funding runway: How to maintain capital efficiency in an improving market
Mar 10, 2026
Blog
Bolster your investor narrative with RWE
Jan 26, 2026
Blog
Investor-ready evidence planning: Why a robust strategy matters to funders
Dec 8, 2025
Playbook
Strategic outsourcing redefined: Building partnerships that propel innovation
Dec 5, 2025